The Download: the mysteries surrounding weight-loss drugs, and the economic effects of AI

What we still don't know about weight-loss drugs Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind Mounjaro and Zepbound, became the first healthcare company in the world to achieve a trillion-dollar valuation. But we also learned that, disappointingly, GLP-1 drugs don't seem to help people with Alzheimer's disease. And that people who stop taking the drugs when they become pregnant can experience potentially dangerous levels of weight gain. On top of that, some researchers worry that people are using the drugs postpartum to lose pregnancy weight without understanding potential risks. All of this news should serve as a reminder that there's a lot we still don't know about these drugs.